Fibromyalgia - Drug Pipeline Landscape, 2023
Description
Fibromyalgia - Drug Pipeline Landscape, 2023
Fibromyalgia is a common chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep, memory and cognitive issues.
Researchers reported that repeated nerve stimulation causes the brain and spinal cord of people with fibromyalgia to change. The conditions conditions that may bring on symptoms, such as: stressors, viral infections or other illnesses like arthritis, anxiety, depression, other mood disorders, PTSD.
Fibromyalgia can be diagnosed if the patient had widespread pain for 3 months or longer. Healthcare professionals use a process of elimination to diagnose fibromyalgia, for concluding that no other condition is causing the pain. Healthcare professionals may rule out other conditions that may have similar symptoms with some tests including complete blood count, Rheumatoid factor, thyroid function tests, anti-nuclear antibody, cyclic citrullinated peptide test etc.
Treatment of fibromyalgia includes medications such as pain relievers, antidepressants and anti-seizure drugs. therapies like physical therapy, occupational therapy and counselling can also be advised.
There are many companies that are actively developing drugs for the treatment of fibromyalgia, including Pfizer, Astellas Pharma, Tonix Pharmaceuticals, Cortene Inc etc.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Fibromyalgia treatment such as Esreboxetine, TNX-102, ASP0819 and others. Key players involved in the development of therapies to treat Fibromyalgia are Aardvark Therapeutics Inc, Astellas Pharma Inc, Cortene Inc, Pfizer, Tonix Pharmaceuticals Inc and others. Two drugs are under late-stage Phase III clinical trials and three drugs are in Phase II clinical trials and some other drugs are under Phase I, IND/CTA Filed and Preclinical stages of development.
Report Highlights
Global Insight Service's, Fibromyalgia - Drug Pipeline Landscape, 2023 report provides an overview of the Fibromyalgia pipeline drugs. This report covers detailed insights on Fibromyalgia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Fibromyalgia pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Fibromyalgia is a common chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep, memory and cognitive issues.
Researchers reported that repeated nerve stimulation causes the brain and spinal cord of people with fibromyalgia to change. The conditions conditions that may bring on symptoms, such as: stressors, viral infections or other illnesses like arthritis, anxiety, depression, other mood disorders, PTSD.
Fibromyalgia can be diagnosed if the patient had widespread pain for 3 months or longer. Healthcare professionals use a process of elimination to diagnose fibromyalgia, for concluding that no other condition is causing the pain. Healthcare professionals may rule out other conditions that may have similar symptoms with some tests including complete blood count, Rheumatoid factor, thyroid function tests, anti-nuclear antibody, cyclic citrullinated peptide test etc.
Treatment of fibromyalgia includes medications such as pain relievers, antidepressants and anti-seizure drugs. therapies like physical therapy, occupational therapy and counselling can also be advised.
There are many companies that are actively developing drugs for the treatment of fibromyalgia, including Pfizer, Astellas Pharma, Tonix Pharmaceuticals, Cortene Inc etc.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Fibromyalgia treatment such as Esreboxetine, TNX-102, ASP0819 and others. Key players involved in the development of therapies to treat Fibromyalgia are Aardvark Therapeutics Inc, Astellas Pharma Inc, Cortene Inc, Pfizer, Tonix Pharmaceuticals Inc and others. Two drugs are under late-stage Phase III clinical trials and three drugs are in Phase II clinical trials and some other drugs are under Phase I, IND/CTA Filed and Preclinical stages of development.
Report Highlights
Global Insight Service's, Fibromyalgia - Drug Pipeline Landscape, 2023 report provides an overview of the Fibromyalgia pipeline drugs. This report covers detailed insights on Fibromyalgia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Fibromyalgia pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
73 Pages
- 1. Introduction
- 1.1 Fibromyalgia - Pipeline Drugs, 2023 - Coverage
- 2.Disease Overview - Fibromyalgia
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3.Fibromyalgia - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4.Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5.Drug Profiles
- 5.1 Clinical Stage Drugs-Phase III
- 5.1.1 Esreboxetine
- 5.1.2 TNX-102
- 5.2 Clinical Stage Drugs-Phase II
- 5.2.1 ASP0819
- 5.2.2 IMC-1
- 5.2.3 NYX-2925
- 5.3 Clinical Stage Drugs-Phase I
- 5.3.1 CT38
- 5.3.2 TRP-8802
- 5.4 Early Stage Drugs-IND/CTA Filed
- 5.4.1 LD04185
- 5.5 Early Stage Drugs-Preclinical
- 5.5.1 ARD-301
- 6.Key Regulatory Designations
- 7.Key Deals
- 8.Key Upcoming Milestones
- 9.Key Companies Involved
- 9.1 Aardvark Therapeutics Inc
- 9.2 Aptinyx
- 9.3 Astellas Pharma Inc
- 9.4 Cortene Inc
- 9.5 Shanghai lvdao pharmaceutical technology co., Ltd
- 9.6 Tonix Pharmaceuticals, Inc.
- 9.7 TRYP Therapeutics
- 9.8 Virios Therapeutics
- 10.Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11.Appendix
- List of Tables
- Table 1.1 Number of Products under Development by Fibromyalgia
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - Esreboxetine/Pfizer
- Table 2.2 Clinical Trial Details - TNX-102/Tonix Pharmaceuticals, Inc.
- Table 2.3 Clinical Trial Details - ASP0819/Astellas Pharma Inc
- Table 2.4 Clinical Trial Details - IMC-1/Virios Therapeutics, Inc
- Table 2.5 Clinical Trial Details - GT-02037/GlyTech, Inc
- Table 2.6 Clinical Trial Details - NYX-2925/Aptinyx
- Table 2.7 Clinical Trial Details - TRP-8802/TRYP Therapeutics
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Fibromyalgia, 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Fibromyalgia, 2023
- Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Fibromyalgia, 2023
- Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Fibromyalgia, 2023
- Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Fibromyalgia, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
